The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose escalation with high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk prostate cancer: Higher PSA control with lower toxicity.
Benjamin Guix
No relevant relationships to disclose
Jose Maria Bartrina
No relevant relationships to disclose
Jose Ignacio Tello
No relevant relationships to disclose
Teresa Maria Lacorte
No relevant relationships to disclose
Ivan Henriquez
No relevant relationships to disclose
Josep Sole
No relevant relationships to disclose
Ines Guix
No relevant relationships to disclose
Guillermo Galdon
No relevant relationships to disclose
Marc Espino
No relevant relationships to disclose